Shazia Alam, Syed Baqir Syum Naqv, Maqsood Ahmed.
Unstable angina direct treatment cost of unstable angina with low molecular weight heparin in conservative management.
Professional Med J Nov ;23(10):1276-80.

Objective: To determine the direct treatment cost of unstable angina (UA) with low molecular weight heparin (LMWH) in conservative management. Study design: Prospective study. Settings: Government cardiovascular hospital and private tertiary care hospital, Karachi. Study period: One year. Method: All 487 patients with either sex having cardiac history of ischemic heart disease, presenting chest pain diagnosed to have unstable angina admitted in hospital for 2-8 days were recruited and entered in study. The current prospective study was designed to analyze the direct treatment cost of UA with LMWH. Data was collected through proforma and results were analyzed by SPSS version 20. Results: Results were represented in terms of percentages, frequencies and means of cost contribution of LMWH. All costs values converted from Pakistani currency (PKR) into US dollars ($) as per exchange rate of 2014. Less number of prescriptions found for fondaparinux (24.85%) than enoxaparin (70%). The estimated mean of drug cost particularly observed in three treatment groups of patients who received enoxaparin, fondaparinux and dalteparin was $36, $ 15 and $ 47 correspondingly. Moreover, 4 days total direct cost of enoxaparin and fondaparinux was $191, $ 84 and 6 days treatment costs $ 149 with dalteparin to treat a single case of UA. It has been found that fondaparinux significantly lowers the cost of care in comparison to enoxaparin and dalteparin. Conclusion: Current analysis concluded that in the treatment of unstable angina, fondaparinux found to be a dominant strategy that simultaneously lowers the cost of care in conservative management.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com